25doc022 10.3205/25doc022 urn:nbn:de:0183-25doc0225 Meeting Abstract Zeitz Zeitz Oliver O

Charité – Universitätsmedizin Berlin, Klinik für Augenheilkunde, Berlin

author Ghorayeb Ghorayeb Ghassan G

West Virginia University Eye Institute, Morgantown, USA

author German Medical Science GMS Publishing House

Düsseldorf

610 20250513 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0613 022 37. Internationaler Kongress der Deutschen Ophthalmochirurgie (DOC) Retina II Nürnberg 20250515 20250517 FP 3.3 TextPurpose: In the 96-week PHOTON study (NCT04429503), aflibercept 8 mg every 12 and 16 weeks (8q12 and 8q16) after 3 monthly doses demonstrated comparable visual and anatomic improvements to aflibercept 2 mg every 8 weeks (2q8) after 5 monthly doses in patients with diabetic macular edema; 93% of patients in the combined aflibercept 8-mg group had a last assigned dosing interval of ≥12 weeks at Week 96. An optional one-year extension (to 156 weeks) evaluated long-term treatment outcomes in patients who continued with aflibercept 8 mg and in those who were switched from aflibercept 2q8 to 8 mg. Methods: Following Week 96, patients initially randomized to 8q12 or 8q16 continued to receive aflibercept 8 mg (8mg group; n=195), while patients initially randomized to 2q8 were switched to aflibercept 8 mg and assigned to 12-week dosing intervals (2q8à8mg group; n=70). From Week 100, dosing intervals could have been shortened at any visit or extended at dosing visits if prespecified criteria were met. Results: At Week 156, both the 8mg and 2q8à8mg groups maintained the visual and anatomic improvements that were achieved at Week 96. In the 2q8→8 mg group, fluid reaccumulation was substantially slower 8 weeks after the first aflibercept 8-mg injection compared with 8 weeks after the aflibercept 2-mg injections these patients received through Week 88. Of patients in the 8 mg group who completed Week 156, 45% had a last completed dosing interval of ≥20 weeks, and 48% had a last assigned dosing interval of ≥20 weeks. Through Week 156, 83% of patients in the 2q8à8mg group had a last assigned dosing interval of ≥12 weeks. No new safety signals were identified through Week 156. Conclusions: Long-term visual and anatomic improvements were maintained with aflibercept 8 mg at extended dosing intervals, with no new safety signals through 156 weeks. The achievement of extended dosing intervals with aflibercept 8 mg in the vast majority of patients, together with the slower fluid reaccumulation observed following a switch from aflibercept 2 mg to 8 mg, supports the longer duration of action of aflibercept 8 mg versus 2 mg. This abstract has been recently submitted and will be presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). 0 0 0 0